REVELATION BIOSCIENCES, INC.

Revelation Biosciences, Inc. (Nasdaq: REVB) is a clinical-stage biopharmaceutical company that became publicly traded through its business combination with Petra Acquisition Inc., a blank-check company sponsored by Petra Acquisition Sponsors LLC that completed its IPO in 2021. Focused on the life sciences and immunology sector, Revelation develops novel therapeutic and prophylactic products targeting innate immune pathways. The company filed an 8-K with the Securities and Exchange Commission on August 6, 2026, disclosing a material corporate event. REVB remains listed on Nasdaq as a post-combination entity. Readers seeking full filing timelines, deal metrics, and real-time SPAC intelligence can sign up for complete data access at SpacDesk.